

---

---

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM S-8**  
**REGISTRATION STATEMENT**

*UNDER*  
*THE SECURITIES ACT OF 1933*

---

**ORAGENICS, INC.**

(Exact name of registrant as specified in its charter)

---

**FLORIDA**  
(State or other jurisdiction of  
incorporation or organization)

**59-3410522**  
(I.R.S. Employer  
Identification No.)

**4902 Eisenhower Boulevard, Suite 125**  
**Tampa, Florida 33634**  
**813-286-7900**

(Address, including zip code, and telephone number, including area code of registrant's principal executive offices)

**2012 EQUITY INCENTIVE PLAN**  
(Full Title of the Plans)

**Alan Joslyn,**  
**President and Chief Executive Officer.**  
**4902 Eisenhower Boulevard, Suite 125**  
**Tampa, Florida 33634**  
**813-286-7900**

(Name, Address and Telephone number of Agent for Service)

*Copies to:*

**Mark A. Catchur, Esquire**  
**Shumaker, Loop & Kendrick, LLP**  
**101 E. Kennedy Blvd., Suite 2800**  
**Tampa, Florida 33602**  
**(813) 229-7600**

---

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer

Accelerated filer

Non-accelerated filer  (do not check if a smaller reporting company)

Smaller reporting company

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

---

#### CALCULATION OF REGISTRATION FEE

TITLE OF SECURITIES TO BE REGISTERED(1)	AMOUNT TO BE REGISTERED(2)	PROPOSED MAXIMUM OFFERING PRICE PER SHARE(3)	PROPOSED MAXIMUM AGGREGATE OFFERING PRICE(3)	AMOUNT OF REGISTRATION FEE(3)
Common Stock \$0.001 Par Value	350,000	\$2.09	\$731,500.00	\$91.07

- (1) The securities to be registered include options and awards to acquire common stock.
- (2) This Registration Statement registers an additional 350,000 shares of Company common stock for issuance pursuant to the Company’s 2012 Equity Incentive Plan (which is an amendment and restatement of the Company’s Amended and Restated 2002 Stock Option and Incentive Plan) (the “Plan”). Pursuant to Rule 416 under the Securities Act of 1933, as amended, this Registration Statement also covers any additional number of shares as may be available under the Plan in the event of a stock dividend, stock split, recapitalization or other similar change to the Common Stock.
- (3) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(c) under the Securities Act of 1933, as amended based upon the closing price per share of our Common Stock as reported on NYSE American, on February 13, 2018.
- 
-

---

**REGISTRATION OF ADDITIONAL SECURITIES****EXPLANATORY NOTE**

This Registration Statement on Form S-8 of Oragenics, Inc. (the “Company”) is being filed to register 350,000 additional shares of Company common stock authorized for issuance under the 2012 Equity Incentive Plan, (the “Plan”) (which is an amendment and restatement of the Company’s 2002 Amended and Restated Stock Incentive Plan), pursuant to General Instruction E to Form S-8. The table below summarizes the Plan, as amended to date and the registration statements previously filed to cover shares authorized for issuance under the Plan.

**Summary Plan Table**

<b>Plan History</b>	<b>Date</b>	<b>Authorized Shares</b>	<b>Post-Split Shares*</b>	<b>Registration Statement</b>
Adoption	November 2002	50,000	5,000	333-110646
Amended and Restated	September 2006	100,000	10,000	333-150716
First Amendment	April 2008	100,000	10,000	333-150716
Second Amendment	October 2009	375,000	37,500	333-163083
Third Amendment	September 2011	500,000	50,000	333-177091
2012 Amended and Restated Equity Incentive Plan	October 2012	2,875,000	287,500	333-184588
First Amendment to 2012 Plan	May 2017	1,500,000	150,000	**
Second Amendment to 2012 Plan	December 2017	2,000,000	200,000	**
Total		7,500,000	750,000	

\* On September 24, 2010, the Company effected a 1 for 20 reverse stock split and on January 19, 2018, the Company effected a 1 for 10 reverse stock split, respectively and the same have been applied to the share amounts indicated as applicable.

\*\* On May 4, 2017, the Company shareholders approved an increase in the number of authorized shares for issuance under the Plan by 150,000 shares on a post-split basis from 400,000 shares to 550,000 shares. On December 1, 2017, the Company shareholders approved an increase in the number of authorized shares for issuance under the Plan by 200,000 shares on a post-split basis from 550,000 shares to 750,000 shares

Pursuant to General Instruction E to Form S-8, the contents of the previously filed Registration Statements, on Form S-8 (Nos. 333-110646, 333-150716, 333-163083, 333-177091 and 333-184588), on November 21, 2003, July 5, 2008, November 13, 2009, September 30, 2011 and October 25, 2012, respectively, are incorporated herein by reference, except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the earlier registration statements are presented herein.

---

**PART I**  
**INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS**

The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Securities Act Rule 428(b)(1).

**PART II**  
**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

This Registration Statement on Form S-8 incorporates by reference the following documents we previously filed with the Securities and Exchange Commission:

- Registration Statement on Form S-8 filed November 21, 2003 (File No. 333-110646);
- Registration Statement on Form S-8 filed July 5, 2008 (File No. 333-150716);
- Registration Statement on Form S-8 filed November 13, 2009 (File No. 333-163083);
- Registration Statement on Form S-8 filed September 30, 2011 (File No. 333-177091)
- Registration Statement on Form S-8 filed October 25, 2012 (File No. 333-184588)
- the Registrant's Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Commission on February 16, 2018; and
- the Registrant's Current Reports on Form 8-K, filed with the Commission on each of January 8, 2018 and January 19, 2018.

All documents filed by the Registrant pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Securities Exchange Act of 1934, as amended, subsequent to the effective date of this Registration Statement, prior to the filing of a post-effective amendment to this Registration Statement indicating that all securities offered hereby have been sold or deregistering all securities then remaining unsold, shall be deemed to be incorporated by reference herein and to be part hereof from the date of filing of such documents. In no event, however, will any information that the Registrant discloses under Item 2.02 or Item 7.01 (and any related exhibits) of any Current Report on Form 8-K that the Registrant may from time to time furnish to the Commission be incorporated by reference into, or otherwise become a part of, this Registration Statement. Any statement contained in any document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed to constitute a part of this Registration Statement, except as so modified or amended, to constitute a part of the Registration Statement.

**Item 8. Exhibits.**

See the Exhibit Index immediately following the signature page which is incorporated herein by reference.

---

## EXHIBIT INDEX

<b>Exhibit Number</b>	<b>Exhibit Description</b>
4.1	<a href="#"><u>2012 Equity Incentive Plan (incorporated by reference as Exhibit 4.1 to Form 8-K filed on October 25, 2012).</u></a>
4.2	<a href="#"><u>First Amendment to 2012 Equity Incentive Plan (incorporated by reference as Exhibit 4.2 to Form 8-K filed on May 5, 2017).</u></a>
4.3	<a href="#"><u>Second Amendment to 2012 Equity Incentive Plan (incorporated by reference as Exhibit 4.3 to Form 8-K filed on December 29, 2017).</u></a>
5.1	<a href="#"><u>Opinion of Shumaker, Loop &amp; Kendrick, LLP, as to the legality of the securities being registered.</u></a>
23.1	<a href="#"><u>Consent of Independent Registered Public Accounting Firm, Mayer Hoffman McCann P.C.</u></a>
23.2	<a href="#"><u>Consent of Shumaker, Loop &amp; Kendrick, LLP to the use of their opinion as an Exhibit to this Registration Statement is included in their opinion filed herewith as Exhibit 5.1.</u></a>
24.1	<a href="#"><u>Power of Attorney (included with the signature page to this Registration Statement).</u></a>

---

## SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, the Company certifies that it has reasonable grounds to believe that it meets all of the requirements for filing Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Tampa, State of Florida this 16<sup>th</sup> day of February 2018.

### Oragenics, Inc.

By: /s/ Alan Joslyn

Alan Joslyn  
President, Chief Executive Officer and  
Principal Executive Officer

## POWER OF ATTORNEY

Each of the undersigned officers and directors of Oragenics, Inc., hereby constitutes and appoints Alan Joslyn and Michael Sullivan, each their true and lawful attorneys-in-fact and agents, for them and in their name, place and stead, in any and all capacities, to sign their names to any and all amendments to this Registration Statement on Form S-8, including post-effective amendments and other related documents, and to cause the same to be filed with the Securities and Exchange Commission, granting unto said attorneys, full power and authority to do and perform any act and thing necessary and proper to be done in the premises, as fully to all intents and purposes as the undersigned could do if personally present, and the undersigned for himself hereby ratifies and confirms all that said attorney shall lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this S-8 Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

<u>Signature</u>	<u>Title</u>	<u>Date</u>
<u>/s/ Alan Joslyn</u> Alan Joslyn	President, Chief Executive Officer, Principal Executive Officer and Director	February 16, 2018
<u>/s/ Michael Sullivan</u> Michael Sullivan	Chief Financial Officer and Principal Accounting Officer	February 16, 2018
<u>/s/ Frederick W. Telling</u> Frederick W. Telling	Chairman of the Board and Director	February 16, 2018
<u>/s/ Robert C. Koski</u> Robert C. Koski	Director	February 16, 2018
<u>/s/ Charles L. Pope</u> Charles L. Pope	Director	February 16, 2018
<u>/s/ Alan W. Dunton</u> Alan W. Dunton	Director	February 16, 2018



Bank of America Plaza 813.229.7600  
101 East Kennedy Boulevard 813.229.1660 fax  
Suite 2800  
Tampa, Florida 33602

---

www.slk-law.com

February 16, 2018

Oragenics, Inc.  
4902 Eisenhower Boulevard, Suite 125  
Tampa, Florida 33634

Re: Registration Statement on Form S-8

Ladies and Gentlemen:

We have assisted Oragenics, Inc., a Florida corporation (the "Company") in connection with the preparation and filing of its Registration Statement on Form S-8 with the Securities and Exchange Commission pursuant to the requirements of the Securities Act of 1933, as amended (the "Act"), for the registration of an additional 350,000 shares of the common stock of the Company, par value \$.001 per share (the "Shares"), issuable under the Company's 2012 Equity Incentive Plan (the "Plan").

In connection with the following opinion, we have examined and have relied upon such documents, records, certificates, statements and instruments as we have deemed necessary and appropriate to render the opinion herein set forth.

On the basis of such examination and our consideration of those questions of law we considered relevant, and subject to the limitations and qualifications in this opinion, we are of the opinion that: (1) the Shares have been duly authorized by all necessary corporate action on the part of the Company; and (2) when issued in accordance with such authorization, the provisions of the Plan and relevant agreements duly authorized by and in accordance with the terms of the Plan, and upon payment for and delivery of the Shares as contemplated in accordance with the Plan, and either (a) the countersigning of the certificate or certificates representing the Shares by a duly authorized signatory of the registrar for the Company's Common Stock, or (b) the book-entry of the Shares by the transfer agent for the Company's Common Stock in the name of The Depository Trust Company or its nominee, the Shares will be validly issued, fully paid and non-assessable.

We are admitted to practice in the State of Florida. This opinion letter is limited to the laws of the State of Florida, and the federal laws of the United States of America as such laws presently exist and to the facts as they presently exist. We express no opinion with respect to the effect or applicability of the laws of any other jurisdiction. We assume no obligation to revise or supplement this opinion letter should the laws of such jurisdictions be changed after the date hereof by legislative action, judicial decision or otherwise.

The undersigned hereby consents to the filing of this opinion as Exhibit 5.1 to the Registration Statement on Form S-8 and to the use of its name in the Registration Statement. In giving such consent we do not admit that we are in the category of persons whose consent is required under Section 7 of the Act.

Very truly yours,

/s/ Shumaker, Loop & Kendrick, LLP  
SHUMAKER, LOOP & KENDRICK, LLP

**Consent of Independent Registered Public Accounting Firm**

We have issued our report dated February 16, 2018, on the financial statements of Oragenics, Inc. included in its Annual Report (Form 10-K) for the year ended December 31, 2017, filed with the Securities and Exchange Commission, which are incorporated by reference in this Registration Statement (Form S-8 No. 333- ). We consent to the incorporation by reference in the Registration Statement of the aforementioned report.

/s/ Mayer Hoffman McCann P.C.  
MAYER HOFFMAN MCCANN P.C.  
Clearwater, Florida  
February 16, 2018